Efsubaglutide alfa

C57BL/6J (male, 18 weeks old, diet-induced obese, body weight >40 g)^[2]

0.290 mg/kg (low dose); 0.290 mg/kg (days 0-6) then 0.871 mg/kg (days 7-41) (medium dose); 0.290 mg/kg (days 0-6) then 0.871 mg/kg (days 7-13) then 1.306 mg/kg (days 14-41) (high dose)

s.c.; twice weekly; 41 days

Reduced body weight by 18.93% (low dose), 25.54% (medium dose), 27.99% (high dose) by day 41.
Reduced liver weight and liver-to-body weight ratio across all doses; medium and high doses resulted in lower liver weights (839.4 mg and 839.7 mg, respectively) and liver-to-body weight ratios (2.53% and 2.64%, respectively) than semaglutide.
Decreased hepatic triglyceride (TG) and total cholesterol (TC) levels with low and high doses; reduced hepatic TG levels only with medium dose.
Reduced steatosis scores to 1.4 (low dose), 1.6 (medium dose), 1.3 (high dose).
Lowered NAFLD Activity Score (NAS) to 3.3 (low dose) and 3.0 (high dose) versus MASH controls' 4.5.
Reduced perisinusoidal collagen content (%PS) to 0.30% (low dose), 0.27% (medium dose), 0.30% (high dose) versus MASH controls' 0.40%.
Reduced the number of thin perisinusoidal collagen fibre bundles (ThinStrPS) to 8.99 (low dose), 7.99 (medium dose), 8.25 (high dose).
Reduced hepatic α-SMA expression with high dose.
Reduced serum alanine aminotransferase (ALT) levels to 54.4 U/L (low dose), 67.5 U/L (medium dose), 55.9 U/L (high dose).
Reduced serum aspartate aminotransferase (AST) levels to 101.0 U/L (low dose), 121.2 U/L (medium dose), 104.9 U/L (high dose).
Reduced fasting blood glucose to 6.19 mmol/L (low dose), 5.02 mmol/L (medium dose), 5.28 mmol/L (high dose); medium and high doses produced greater reductions than semaglutide.
Reduced serum insulin levels to 1.35 ng/mL (high dose).
Reduced serum TC, low-density lipoprotein cholesterol (LDL-c), and high-density lipoprotein cholesterol (HDL-c) levels across all doses; reduced serum TG levels with low and high doses.